Breath Therapeutics

Breath Therapeutics' Chief Program: A Leading Combination of Treatment/Medical Technology Devices for Bronchiolitis Obliterans Syndrome (BOS), a Life-Threatening Disease Occurring in 65% of Post-Lung Transplant Patients. The Company Utilizes an Optimized Version of PARI Pharma's eFlow Nebulizer to Administer a Liposomal Formulation of the Immunosuppressive Drug Cyclosporine A, Which Allows for Online Monitoring of Treatment Adherence.Breath Therapeutics Focuses on Advanced and First-Class Inhalation Therapies for Severe Respiratory Diseases. For Its Clinical Development, the Company Employs Patented Drug Formulations Specifically Designed for Inhalation Administration, Using Exclusively Licensed High-Performance Nebulizers. Breath Therapeutics Concentrates on Comprehensive Treatment Solutions That Interact Between Diagnosis, Treatment, and eHealth Therapy Control. The Clinical Development Program Is Addressing the Treatment of Bronchiolitis Obliterans Syndrome (BOS) in Post-Lung Transplant Patients.